Bank of New York Mellon Corp Raises Position in Aclaris Therapeutics Inc (NASDAQ:ACRS)

Bank of New York Mellon Corp lifted its stake in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 24.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 110,015 shares of the biotechnology company’s stock after buying an additional 21,754 shares during the period. Bank of New York Mellon Corp owned about 0.41% of Aclaris Therapeutics worth $2,839,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Franklin Resources Inc. lifted its stake in Aclaris Therapeutics by 55.4% during the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after purchasing an additional 697,104 shares during the period. Westfield Capital Management Co. LP lifted its stake in Aclaris Therapeutics by 79.6% during the second quarter. Westfield Capital Management Co. LP now owns 1,249,254 shares of the biotechnology company’s stock worth $33,880,000 after purchasing an additional 553,752 shares during the period. FMR LLC lifted its stake in Aclaris Therapeutics by 14.6% during the second quarter. FMR LLC now owns 1,896,206 shares of the biotechnology company’s stock worth $51,425,000 after purchasing an additional 242,269 shares during the period. Nexthera Capital LP lifted its stake in Aclaris Therapeutics by 204.9% during the second quarter. Nexthera Capital LP now owns 340,000 shares of the biotechnology company’s stock worth $9,221,000 after purchasing an additional 228,500 shares during the period. Finally, State Street Corp lifted its stake in Aclaris Therapeutics by 67.1% during the second quarter. State Street Corp now owns 330,755 shares of the biotechnology company’s stock worth $8,971,000 after purchasing an additional 132,866 shares during the period. Institutional investors and hedge funds own 92.02% of the company’s stock.

Shares of Aclaris Therapeutics Inc (NASDAQ ACRS) opened at $25.00 on Friday. Aclaris Therapeutics Inc has a fifty-two week low of $21.32 and a fifty-two week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million for the quarter, compared to analyst estimates of $2.00 million. sell-side analysts anticipate that Aclaris Therapeutics Inc will post -2.59 earnings per share for the current year.

A number of brokerages have commented on ACRS. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Monday, January 8th. Zacks Investment Research cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, BidaskClub upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $39.20.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/bank-of-new-york-mellon-corp-grows-position-in-aclaris-therapeutics-inc-acrs.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply